^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JCAR024
i
Other names: JCAR024, JCAR 024, JCAR-024, ROR-1 CAR T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
ROR1-targeted CAR-T immunotherapy
Related drugs:
2years
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov)
P1, N=21, Terminated, Fred Hutchinson Cancer Research Center | N=60 --> 21 | Trial completion date: Dec 2023 --> Sep 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> May 2021; Terminated due to slow accruals.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
EGFR mutation • HER-2 negative • ALK mutation • ROR1 expression
|
cyclophosphamide • JCAR024
2years
LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors (AACR 2022)
In preclinical studies LYL797 cells reprogrammed with Gen-R and Epi-R led to improved functional activity in the presence of ROR1+ tumor cells compared to conventional ROR1 CAR T cells.Additional studies are underway to determine the mechanisms by which antitumor activity of LYL797 in ROR1-positive solid tumor xenograft models is enhanced. LYL797 is anticipated to enter into Phase 1 clinical trials for TNBC and NSCLC in 2022.
CAR T-Cell Therapy
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • JUN (Jun proto-oncogene)
|
ROR1 expression • ROR1 positive
|
LYL797 • JCAR024
over2years
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov)
P1, N=60, Recruiting, Fred Hutchinson Cancer Research Center | Trial completion date: Dec 2037 --> Dec 2023
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
EGFR mutation • HER-2 negative • ALK mutation • ROR1 expression
|
JCAR024
3years
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov)
P1, N=60, Recruiting, Fred Hutchinson Cancer Research Center | Trial completion date: Dec 2036 --> Dec 2037 | Trial primary completion date: Dec 2021 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
EGFR mutation • HER-2 negative • ALK mutation • ROR1 expression
|
JCAR024
almost4years
[VIRTUAL] Engineered variants of Neo-2/15 potently expand CAR-T cells and promote antitumor activity in lymphoma and solid tumor mouse models (AACR-II 2020)
In a B cell tumor xenograft model, targeted Neo-2/15 effectively increased CAR-T cell expansion and prolonged survival compared to treatment with CAR-T cells and non-targeted Neo-2/15. Together, these results show that engineered versions of Neo-2/15 induce robust expansion of CAR-T cells and can enhance their antitumor activity.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
TP53 mutation • KRAS mutation • KRAS overexpression
|
JCAR024 • NL-201
4years
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov)
P1, N=60, Suspended, Fred Hutchinson Cancer Research Center | Recruiting --> Suspended
Clinical • Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
EGFR mutation • HER-2 negative • ALK mutation • ROR1 expression
|
JCAR024
Share via
